Verastem, Inc. shifts focus to VS-7375 for KRAS G12D tumors after ending RAMP-203. Click to learn about VSTM's key catalysts ...

Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

Paying homage to Parkway Drive's Ben Gordon, Polaris's Dan Furnari, Stray From The Path's Craig Reynolds & more The post RedHook’s Alex Powys Talks 10 Drummers Who Influenced His Playing On ‘Mutation’ ...

Ultragenyx Pharmaceutical (RARE) remains a Sell after its Phase 3 OI program failed to meet primary fracture reduction ...

Angelina Jolie is reportedly preparing to leave Los Angeles behind as she plans a new life abroad focused on privacy, freedom ...

Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...

A single microscopic change in our DNA can permanently alter how the brain is built, locking in developmental problems that ...

TRITON3 trial data support FDA traditional approval of rucaparib for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer.

Ultragenyx and Mereo BioPharma hit 52-week low after disappointing results from Phase 3 studies for Osteogenesis Imperfecta ...

SELLAS Life Sciences Virtual R&D Day -- October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 ...

NDA submissions for bezuclastinib in Gastrointestinal Stromal Tumors (GIST) and Advanced Systemic Mastocytosis (AdvSM) are on-track for the first half of 2026 based on the strength of clinical results ...